For those cases of CLL that displayed little or no spontaneous recovery of S1PR1 expression during cell culture, we adopted a complementary approach involving treatment with BCR signaling inhibitors to block presumed endogenous BCR signaling. The gene discussed is S1PR1; the disease is B-cell chronic lymphocytic leukemia.